Orexin receptor

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

Wednesday, June 9, 2021 - 3:31am

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Key Points: 
  • TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.
  • Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).
  • Eisai considers neurology a therapeutic area of focus.
  • Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

Insomnia Data 2020: US Leads in Global Insomnia Clinical Trials, Germany Leads Major European Markets and Japan Has Top Spot in Asia

Thursday, May 21, 2020 - 3:45pm

It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).

Key Points: 
  • It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).
  • The approved drugs in the insomnia space target GABA-A receptor, hypocretin/orexin receptor, chloride channel 2, chloride, melatonin receptor, histamine H1 receptor, and potassium channels.
  • Germany leads the major European markets, while Japan has the top spot in Asia.
  • Takeda leads the industry sponsors with the highest overall number of clinical trials for insomnia, followed by Merck & Co.

2020 Market Spotlight: Insomnia -- Eisai Buys Out Global Rights to Lemborexant - ResearchAndMarkets.com

Monday, March 30, 2020 - 1:27pm

It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).

Key Points: 
  • It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).
  • The approved drugs in the insomnia space target GABA-A receptor, hypocretin/orexin receptor, chloride channel 2, chloride, melatonin receptor, histamine H1 receptor, and potassium channels.
  • The largest proportion of industry-sponsored drugs in active clinical development for insomnia are in Phase III, with only one drug in the NDA/BLA phase.
  • Takeda leads the industry sponsors with the highest overall number of clinical trials for insomnia, followed by Merck & Co.

Orexin Receptor Type 2, Pipeline Review, H2 2019 - Inexia Ltd, Takeda Pharmaceutical & Idorsia Pharmaceutical Ltd - ResearchAndMarkets.com

Tuesday, January 21, 2020 - 9:38am

The "Orexin Receptor Type 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Orexin Receptor Type 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene.
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 8 molecules.
  • The latest report Orexin Receptor Type 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

U.S. FDA Approves Eisai's DAYVIGO™ (lemborexant) for the Treatment of Insomnia in Adult Patients

Monday, December 23, 2019 - 1:05pm

Patients were randomized to placebo (n=325), DAYVIGO 5 mg (n=323), or DAYVIGO 10 mg (n=323) once nightly.

Key Points: 
  • Patients were randomized to placebo (n=325), DAYVIGO 5 mg (n=323), or DAYVIGO 10 mg (n=323) once nightly.
  • Patients were randomized to placebo (n=208), DAYVIGO 5 mg (n=266) or 10 mg (n=269), or active comparator (n=263) once nightly.
  • DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • Patients with Compromised Respiratory Function:
    The effect of DAYVIGO on respiratory function should be considered for patients with compromised respiratory function.